Medical Condition

dyspnea asthmatic

Total Trials

2

Recruiting Now

2

Trial Phases

Various

Asthma clinical trials are increasingly stratified by phenotype — Type 2 high (eosinophilic, IgE-mediated) versus Type 2 low (neutrophilic or paucigranulocytic) — because this distinction predicts response to biologic therapies. The anti-IL-5, anti-IL-4/13, and anti-TSLP antibody classes have revolutionized severe asthma management, and trials now aim to achieve full remission rather than just symptom control.

Trials evaluate dupilumab combinations, tezepelumab (anti-TSLP) in Type 2 low asthma, itepekimab, biologic step-down strategies, and oral corticosteroid-sparing approaches. Digital inhalers with adherence monitoring are being validated as outcomes tools. Bronchial thermoplasty for severe non-biologic-responsive patients remains an active surgical comparator.

Top Sponsors

RWTH Aachen University 1 trial

University of Campinas, Brazil 1 trial

Recruiting Clinical Trials

NCT05903001

Recruiting

Diaphragmatic Function as a Biomarker

RWTH Aachen University

View Trial →

NCT06772922

Recruiting

Effects of a Pulmonary and Cardiovascular Rehabilitation Program

University of Campinas, Brazil

View Trial →

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology